

Sr No	Project Proposal Title	PI of study	Department	Sponsor	Start	Completed	Budget
1	“Prevalence of microalbuminuria as a marker of early nephropathy in obese non-DM and non-hypertensive patients with reference to adipokine levels”.	Dr. Varsha Bhatt	Medicine & clinical trial / vaccine trial unit	ICMR	2019	Completed in 2022	15,17,513/-
2	“A phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults”.	Dr. Varsha Bhatt	Medicine & clinical trial / vaccine trial unit	Serum Institute of India Private Limited (SIPL) and ICMR (Co-sponsor) CRO- PPD pharmaceuticals	Mar 2021	Completed in MAY 22	35,56,662/-
3	Randomized, Phase I/II, Placebo-controlled, Dose-Ranging, study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy adult subjects	Dr. Prakash Shende	Medicine & clinical trial / vaccine trial unit	Gennova Biopharmaceuticals Limited CRO- DiagnoSearch Life Sciences Pvt. Ltd.	May 2021	Completed in 2022	81,716/-
4	A Prospective, Multicentre, Randomized, Active-	Dr. Prakash Shende	Medicine & Clinical trial / vaccine Trial unit	Gennova Biopharmaceuticals Limited	21 Sep 2021	Completed in 2023	36,68,057/-

	controlled, Observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects			CRO- DiagnoSearch Life Sciences Pvt. Ltd.			
5	ICMR-WHO Solidarity Trial Plus: - “An international randomised trial of additional treatments for COVID-19 in hospitalised patients	Dr. Shubhangi Kanitkar	Medicine & Clinical trial / vaccine Trial unit	ICMR and WHO	Oct 2021	Completed in 2023	4,57,269/-
6	“National Clinical Registry for COVID-19”	Dr. Dr. Sachin K. Shivnitwar	Medicine & Clinical trial / vaccine Trial unit	ICMR	2021	ONGOING	34,05,192
7	RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)	Dr. Shubhangi Kanitkar	Medicine & Clinical trial / vaccine Trial unit	University of Oxford, UK India Co-Ordinator-ICMR	14 May 2022	Completed in 2023	2,97,997/-
8	A phase 3, observer-blind, randomized, controlled study to evaluate the safety and immunogenicity of a booster dose of Covovax in Indian adults who have	Dr. Srikanth Tripathy	Clinical trial / vaccine Trial unit	Serum Institute of India Private Limited (SIPL) and ICMR (Co-sponsor)	May 2022	Completed in May 2023	11,70,998/-

	received primary vaccination against COVID-19			CRO- PPD pharmaceuticals			
9	A prospective, multi-center, single arm, open label, study to evaluate safety and efficacy of RanizuRel™ containing Ranibizumab for intra-vitreous injection, manufactured by Reliance Life Sciences, Pvt. Ltd. India in patients with neovascular (wet) age-related macular degeneration.	Dr. Nilesh Giri	Ophthalmology & Clinical trial / vaccine Trial unit	Reliance Life Sciences Pvt. Ltd	Sep 2022	Ongoing	11,63,600/-
10	A Randomized, Double-Blind, Vehicle-Controlled, Three Ann, Parallel Group, Multi-Centric, Clinical Study to Establish the Therapeutic Equivalence of Tacrolimus 0.1% Topical Ointment of Intas Pharmaceuticals Limited with Protopic® 0.1% Topical Ointment in Adult Patients with Moderate to Severe Atopic Dermatitis	Dr. Hemant Talnikar	Dermatology & Clinical trial / vaccine Trial unit	Intas Pharmaceuticals Limited CRO-Lambda Therapeutic research	Oct 2022	Completed. Close out pending	3,07,727/-
11	A Randomized, Double-Blind, Vehicle-Controlled, Three Ann, Parallel Group, Multi-Centric, Clinical Study to Establish the Therapeutic Equivalence of Tacrolimus 0.3% Topical Ointment of Intas Pharmaceuticals Limited with Protopic® 0.3% Topical Ointment in Adult	Dr. Hemant Talnikar	Dermatology & Clinical trial / vaccine Trial unit	Intas Pharmaceuticals Limited CRO-Lambda Therapeutic research	Oct 2022	Completed. Close out pending	1,95,993/-

	Patients with Moderate to Severe Atopic Dermatitis						
12	LRP/LUBT010/2016/008: A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 with Lucentis® in Patients with Neovascular Age-Related Macular Degeneration	Dr. Nilesh Giri	Ophthalmology & Clinical trial / vaccine Trial unit	LUPIN pharmaceuticals Pvt. Ltd CRO- IQVIA	Oct 2022	Ongoing	10,76,454/-
13	A Prospective, Multi-centre, Open-labelled, Randomized, Phase II study seamlessly followed by a Phase III study to evaluate the Safety, Tolerability and Immunogenicity of GEMCOVAC-OM as a booster in Subjects 18 years of age and older.	Dr Vikram Vikhe	Medicine & Clinical trial / vaccine Trial unit	Gennova Biopharmaceutic als Limited CRO-JSS Medical Research Asia Pacific Pvt .Ltd.	Nov 2022	Completed. Close out pending	64,53,000/-
14	A prospective, post marketing clinical follow up study to evaluate the safety and Performance of Sirolimus Eluting Cobalt Chromium Coronary Stent System in Real World Indian population.	Dr Susheel Kumar Malani	Department of Cardiology & Clinical trial / vaccine Trial unit	Translumina Therapeutics LLP	Nov 2022	Ongoing	1,29,625
15	A Phase III, Prospective, Randomized, Parallel group, Double-blind, Multicentre	Dr. Nilesh Giri	Ophthalmology & Clinical trial / vaccine Trial unit	LUPIN pharmaceuticals Pvt. Ltd	Apr 2023	Ongoing	13,47,005/-

	Study to Compare the Efficacy, Safety, and Immunogenicity of Lupin's Aflibercept with Eylea® in Patients with Neovascular Age-Related Macular Degeneration						
16	Factors associated with sudden deaths among adults aged 18–45 years, India: Multicentric matched case-control study	Dr. Sachin Shivnitwar	Medicine & Medical Research	ICMR	May 2023	ONGOING	1,50,000
17	Effect of COVID-19 vaccine on thrombotic events among 18–45-year-old population in India, 2022: Multicentric hospital-based matched Case control study	Dr. Sachin Shivnitwar	Medicine & Medical Research	ICMR	May 2023	ONGOING	1,68,700
18	A Prospective, Multi-centre, Single-arm, Phase IV Study to Assess the Safety and Efficacy of Fixed Dose Combination of Brinzolamide and Timolol Ophthalmic Suspension to Decrease Intraocular Pressure (IOP) in Adult Patients with Open-angle Glaucoma or Ocular Hypertension for whom Monotherapy Provides Insufficient IOP Reduction." ICR/22/002	Dr. Megha Ramnik Kotecha	Ophthalmology & Clinical trial / vaccine Trial unit	SUN PHARMA	May-23	ONGOING	4,59,084
19	Prospective, multi-center, randomized, open label, active control, phase 2 clinical study to evaluate	Dr. Srikanth Tripathy	Clinical trial / Vaccine Trial unit	Reliance Life Sciences Pvt. Ltd	11-Oct-23	ONGOING	9,10,960

	immunogenicity, safety and tolerability of single heterologous booster dose of RelCoVax® (Protein Subunit Vaccine of Reliance Life Sciences against SARS-CoV-2 Virus) with Corbevax® (Protein Subunit Vaccine of Biological E Ltd. against SARS-CoV-2 Virus)						
20	A Prospective, multi-center, open label, single-arm, phase I study to evaluate the safety of GBL1204 in patients with neovascular age-related macular degeneration.	Dr. Nilesh Giri	Ophthalmology & Clinical trial / vaccine Trial unit	Gennova Biopharmaceuticals Limited	Not yet started- IEC approval received (DCGI Approval Pending)	Not yet started. DCGI approval pending.	
21	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophilized) – “DengiAll” of Panacea Biotec Limited in Healthy Indian Adults	Dr. Shubhangi Kanitkar	Medicine & Clinical trial / vaccine Trial unit	ICMR & Panacea Biotec Limited	Not yet started. DCGI Final Approval Pending	Not yet started. DCGI Final Approval Pending	
22	A Phase 3, Multicenter, Open-label, Rater-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline for the Treatment of Multibacillary Leprosy When Combined With Rifampicin and Clofazimine [LIGHT]	Dr Ayush Gupta	Dermatology & Clinical trial / vaccine Trial unit	Johnson & Johnson Innovative Medicine	Our Site has been selected, Final version of protocol will be available in December. Project will start in Jan 2024.	Not yet started. Protocol not yet finalized. Will be finalized in Dec 2023.	

23	“Ultrasound-guided radiofrequency ablation of uterine fibroids with the GYIDE system” short-term evaluation of effect of treatment on quality of life and symptom severity.	Dr Meenal Patvekar	OBGY , DPU Cell, & Clinical trial / vaccine Trial unit	BioAgile Therapeutics Pvt. Ltd.(CRO)	Site selected. Funds awaited from funding agency..	Not yet started. Awaiting funds from funding agency.	
24	A Prospective, Randomized, Active Controlled, Double-blind, Multicenter Phase III Clinical Study to Evaluate the Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Adults.	Dr. Srikanth Tripathy	Clinical trial / vaccine Trial unit	Clinical Research Network India, (CRO)	Site selected. DCGI permission awaited	Site selected. DCGI permission awaited	
25	A Randomized, Multicenter, Open Label, Comparative Study to Evaluate the Immunogenicity and Reactogenicity of a Fully Liquid Pentavalent DTwP-HepB-Hib Vaccine [MyFive™] of Panacea Biotec Ltd. With Pentavalent DTwP-HepB-Hib Vaccine [Pentanal SD®] of Serum Institute of India Ltd. following Primary immunization in Healthy Infants.	Dr Shailaja Mane	Pediatric Department & Clinical trial / vaccine Trial unit	Panacea Biotec Limited (Sponsor) & Clinical Research Network India, (CRO)	Site selected. DCGI permission awaited .	Site selected. DCGI permission awaited	
26	A Prospective, Randomized, Observer Blinded, Parallel, Active Controlled,	Dr Shailaja Mane & Dr Tripathy	Pediatric Department & Clinical trial / vaccine Trial unit	Panacea Biotec Limited (Sponsor) & Clinical	Site selected. DCGI permission awaited	Site selected. DCGI permission awaited	

<p>Multicentric, Non-Inferiority Phase III Study to Evaluate The Immunogenicity And Safety Of Group ACYW135 Meningococcal Conjugate Vaccine in Comparison To a Marketed Meningococcal Vaccine In Healthy Indian Subjects.</p>			<p>Research Network India, (CRO)</p>			
---	--	--	--------------------------------------	--	--	--